Business
Neurocrine Biosciences Announces Results from the Real-World RE-KINECT™ Study Published in the Journal of Patient-Reported Outcomes Demonstrating the Effects of Possible Tardive Dyskinesia (TD) on Patient Health and Social Functioning
SAN DIEGO, March 9, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that new data from RE-KINECT™, the largest real-world,
About this update from Neurocrine Biosciences, Inc.
[{"type":"text","content":"SAN DIEGO, March 9, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that new data from RE-KINECT™, the largest real-world, observational, multicenter study of antipsychotic-treated patients with possible tardive dyskinesia (TD), was published in the Journal of Patient-Reported Outcomes.1 The analysis assessed the effects of possible TD, defined as clinician-confirmed presence of abnormal involuntary movements, on patient health and social functioning. It demonstrated that it's important for clinicians to not only assess possible presence and severity of TD, but to also assess patient awareness of their own abnormal movements and the impact of these symptoms on the patients' overall wellness and ability to function to determine optimal management strategies.\n\n \n \n \n \n \n \n\n \nThe data demonstrated physical wellness and social functioning were diminished, as observed in the study, particularly among patients with possible TD who were aware of their involuntary movements and rated those movements as having \"a lot\" of impact on daily activities. In addition, severity terms or standardized assessments that label movements as \"mild\" and \"severe\" are inherently subjective and patients who are aware of their movements might find even \"milder\" movements to be disruptive, debilitating, or embarrassing.\n\"Insights from RE-KINECT suggest clinician-rated severity of TD may not always correlate with patient perceptions on the impact of TD on their daily lives,\" said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences. \"In addition to assessing the presence and severity of patients' abnormal movements, clinicians should ask patients about how their uncontrollable movements affect their daily activities and consider these impacts when making treatment plans.\"\n\"While awareness around the impact of TD has increased among healthcare providers, patients, and caregivers, there are limited comprehensive, quantitative assessments specifically measuring the health-related quality of life impact the condition has on patients,\" said Stanley N. Caroff, M.D., Professor of Psychiatry at the University of Pennsylvania Perelman School of Medicine. \"The findings from this RE-KINECT analysis are useful for understanding the impact of TD on patients' overall health, physical wellbeing an...